EBS News and Press, Emergent Biosolutions Inc. From 02/24/22

Emergent BioSolutions Inc. (EBS) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Bob Burrows - IR Officer Bob Kramer - President and CEO Rich Lindahl - CFO Adam Havey - Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald...

Emergent Biosolutions press release (NYSE:EBS): Q4 Non-GAAP EPS of $4.50 beats by $0.08. Revenue of $723.2M (+24.0% Y/Y) beats by $46.28M. Updated FY 2022 Guidance: Revenue now expected to range between $1.3-$1.4B, vs. prior guidance of $1.4-$1.5B, vs. consensus of $1.44B; Adjusted EBITDA to ...

Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidance Updates full year 2022 guidance; provides guidance on Q1 2022 total revenues GAITHERSBURG, Md., F...

Emergent BioSolutions has been an exiled ticker following the vaccine mix-up at the company’s Bayview Facility last year. Although the company has addressed the issues in Bayview, it looks as if the market has expelled EBS as a good investment at this point in time. I still...

GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for fu...

GAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022. “Creating and leading Emergent has been the honor of my life, and it wo...

Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpoint Reports preliminary 2021 total revenues of $1.78 billi...

Emergent BioSolutions (NYSE:EBS) announces the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine can...

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vacc...

A couple of retailers saw their stocks plummet in Tuesday's pre-market action despite quarterly earnings that nominally beat expectations. Best Buy (NYSE:BBY) and Urban Outfitters (NASDAQ:URBN) posted double-digit percentage declines on signs that sales won't be able to keep up their recent b...